

References

I-9088

1. Neupogen (filgrastim) injection, for subcutaneous or intravenous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 04/2023.
2. Granix (tbo-filgrastim) injection, for subcutaneous use [package insert]. Teva Pharmaceuticals USA, Inc. North Wales, PA. Revised 11/2019.
3. National Comprehensive Cancer Network (NCCN). NCCN Drugs & Biologics Compendium®. Tbo-filgrastim. 2024.
4. Smith TJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2015;33(28):3199-3212.
5. Pettengell R, Bias P, Mueller U, et al. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. *Supportive Care In Cancer: Official Journal Of The Multinational Association Of Supportive Care In Cancer*. 2016;24(6):2677-2684.
6. Gascón P, Aapro M, Gascón P, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). *Support Care Cancer*. 2016;24(2):911-925.
7. Brito M, Esteves S, André R, et al. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: A non-interventional cohort study. *Support Care Cancer*. 2016;24(2):597-603.
8. Leukine (sargramostim) injection, for subcutaneous or intravenous use [package insert]. Partner Therapeutics, Inc. Lexington, MA. Revised 08/2023.
9. Neulasta (pegfilgrastim) injection, for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 02/2021.
10. Zarxio (filgrastim-sndz) injection, for subcutaneous or intravenous use [package insert]. Sandoz Inc. Princeton, NJ. Revised 08/2019 03/2021.
11. National Comprehensive Cancer Network (NCCN). Filgrastim. NCCN Drugs and Biologics Compendium®. 2024.
12. National Comprehensive Cancer Network (NCCN). Filgrastim-sndz. NCCN Drugs and Biologics Compendium®. 2024.
13. National Comprehensive Cancer Network (NCCN). Pegfilgrastim. NCCN Drugs and Biologics Compendium®. 2024.

14. National Comprehensive Cancer Network (NCCN). Sargramostim. NCCN Drugs and Biologics Compendium®. 2024.
15. National Comprehensive Cancer Network (NCCN). Filgrastim-aafi. NCCN Drugs and Biologics Compendium®. 2024.
16. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-bmez. NCCN Drugs and Biologics Compendium®. 2024.
17. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-jmdb. NCCN Drugs and Biologics Compendium®. 2024.
18. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-cbqv. NCCN Drugs and Biologics Compendium®. 2024.
19. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Filgrastim.
20. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Filgrastim-sndz.
21. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Pegfilgrastim.
22. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Tbo-filgrastim.
23. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Sargramostim.
24. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Filgrastim-aafi.
25. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Pegfilgrastim-bmez.
26. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Pegfilgrastim-jmdb.
27. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Pegfilgrastim-cbqv.
28. Micromedex DrugDex Compendium®. 2024. Filgrastim.
29. Micromedex DrugDex Compendium®. 2024. Filgrastim-sndz.
30. Micromedex DrugDex Compendium®. 2024. Pegfilgrastim.
31. Micromedex DrugDex Compendium®. 2024. Tbo-filgrastim.
32. Micromedex DrugDex Compendium®. 2024. Sargramostim.
33. Micromedex DrugDex Compendium®. 2024. Filgrastim-aafi.
34. Micromedex DrugDex Compendium®. 2024. Pegfilgrastim-bmez.
35. Micromedex DrugDex Compendium®. 2024. Pegfilgrastim-jmdb.
36. Micromedex DrugDex Compendium®. 2024. Pegfilgrastim-cbqv.
37. Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, and Bowe A. A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia. *J Manage Care Spec Pharm.* 2017;23(12):1221-1226.
38. Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. *Support Care Cancer.* 2017;25:439-447.

39. Fulphila (pegfilgrastim-jmdb) injection, for subcutaneous use [package insert]. Mylan Institutional LLC. Rockford, IL. Revised 06/2023.
40. Nivestym™ (filgrastim-aafi) for subcutaneous or intravenous injection [package insert]. Lake Forest, IL. Hospira Inc., a Pfizer Company. Revised 08/2023.
41. Federman N, Dragomir MD, Kizyma Z, Lebedev V, Roganovic J, Bias P, et al. A phase 2, international, multicenter, prospective clinical trial of subcutaneous tbo-filgrastim in pediatric patients with solid tumors undergoing chemotherapy. *Blood*. 2017;130:2271.
42. Udenyca (pegfilgrastim-cbqv) injection, for subcutaneous use [package insert]. Coherus BioSciences, Inc. Redwood City, CA. Revised 03/2023.
43. Nakov R, Gattu S, Wang J, Velinova M, Schaffar G, & Skerjanec A. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. *J Clin Pharmacol*. 2018;84(12):2790-2801.
44. Ziextenzo™ (pegfilgrastim-bmez) injection, for subcutaneous use [package insert]. Sandoz, Inc. Princeton, NJ. Revised 09/2022.
45. Kuan JW, Su AT, Leong CF. Pegylated granulocyte-colony stimulating factor versus non-pegylated granulocyte-colony stimulating factor for peripheral blood stem cell mobilization: A systematic review and meta-analysis. *Journal of Clinical Apheresis*. 2017;32(6):517-542.
46. Halim LA, Márquez M, Maas-Bakker RF, Castañeda-Hernández G, Jiskoot W, Schellekens H. Quality comparison of biosimilar and copy filgrastim products with the innovator product. *Pharmaceutical Research*. 2018;35(11):1-12.
47. Nyvepria™ (pegfilgrastim-apgf) injection, for subcutaneous use [package insert]. Hospira, Inc. Lake Forest, IL. Revised 04/2021.
48. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-apgf. NCCN Drugs and Biologics Compendium®. 2024.
49. Releuko® (filgrastim-ayow) injection, for subcutaneous or intravenous use [package insert]. Amneal Biosciences, Inc. Bridgewater, NJ. Revised 09/2023.
50. Micromedex DrugDex Compendium®. 2024. Filgrastim-ayow.
51. National Comprehensive Cancer Network (NCCN). Filgrastim-ayow. NCCN Drugs and Biologics Compendium®. 2024.
52. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Generic Drug Filgrastim-ayow.
53. Stimufend® (pegfilgrastim-fpgk) injection, for subcutaneous use [package insert]. Fresenius Kabi, LLC. Lake Zurich, IL. Revised 09/ 2023.
54. Micromedex DrugDex Compendium®. 2024. Pegfilgrastim-fgpk
55. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-fgpk. NCCN Drugs and Biologics Compendium®. 2024.

56. Fylnetra® (pegfilgrastim-pbbk) injection, for subcutaneous use [package insert]. Amneal Biosciences, Inc. Bridgewater, NJ. Revised 05/2022.
57. Micromedex DrugDex Compendium®. 2024. Pegfilgrastim-pbbk.
58. National Comprehensive Cancer Network (NCCN). Pegfilgrastim-pbbk. NCCN Drugs and Biologics Compendium®. 2024.
59. Rolvedon™ (eflapegrastim-xnst) injection, for subcutaneous use [package insert]. Spectrum Pharmaceuticals, Inc. Irvine, CA. Revised 06/2023.
60. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Eflapegrastim.
61. Micromedex DrugDex Compendium®. 2024. Eflapegrastim-xnst.
62. Ryzneuta® (efbemalenograstim alfa-vuxw) injection, for subcutaneous use [package insert]. Evibe Biotechnology, Singapore. Revised 11/2023
63. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Efbemalenograstim alfa.
64. Micromedex DrugDex Compendium®. 2024. Efbemalenograstim alfa-vuxw.
65. laspy J, Bondarenko I, Burdaeva O, et al. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. *Support Care Cancer*. 2023;32(1):34.